

**SCHEDULE 2 - TEMPLATE: CPO Ltd representing Boehringer Ingelheim in Cyprus (2017)**

Date of publication: 21/06/2018

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
<b>HCPs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount	
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount	
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount	
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						N/A	N/A	7,410 €	16,395 €	Aggregate HCPs	Aggregate HCPs	Optional
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						N/A	N/A	25	25	number	number	Optional
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						N/A	N/A	%	%	%	%	N/A
<b>HCOs</b>												
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	CYPRUS SOCIETY FOR THE STUDY OF DIABETES					Yearly amount	4,400 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΙΝΣΤΙΤΟΥΤΟ ΜΕΛΕΤΗΣ ΕΡΕΥΝΑΣ & ΕΚΠΑΙΔΕΥΣΗΣ ΓΙΑ ΤΟ ΣΑΚΧΑΡΩΔΗ ΔΙΑΒΗΤΗ ΚΑΙ ΤΑ ΜΕΤΑΒΟΛΙΚΑ ΝΟΣΗΜΑΤΑ					Yearly amount	1,000 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΚΥΠΡΙΑΚΗ ΕΤΑΙΡΕΙΑ ΠΑΘΟΛΟΓΙΑΣ					Yearly amount	1,700 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΙΔΡΥΜΑ MEDICALERT					Yearly amount	500 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΚΑΡΔΙΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ ΚΥΠΡΟΥ					Yearly amount	2,000 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΚΥΠΡΙΑΚΗ ΕΤΑΙΡΕΙΑ ΑΓΓΕΙΑΚΗΣ ΚΑΙ ΕΝΔΑΓΓΕΙΑΚΗΣ ΧΕΙΡΟΥΡΓΙΚΗΣ					Yearly amount	1,125 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΕΤΑΙΡΕΙΑ ΚΥΠΡΟΥ					Yearly amount	4,100 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
						Yearly amount		Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>												
<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Optional
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						number	number	number	number	number	number	Optional
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						%	%	%	%	%	%	N/A
<b>R &amp; D</b>												
<i>AGGREGATE DISCLOSURE</i>												
Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											TOTAL AMOUNT	OPTIONAL

**SCHEDULE 2 - TEMPLATE: CPO Ltd representing Boehringer Ingelheim in Cyprus (2016)**

Date of publication: 30/06/2017

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>		
						Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees		Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs	<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCP</b> (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount		
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount		
						N/A	N/A	Yearly amount	Yearly amount	Yearly amount	Yearly amount		
	<b>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</b>												
	<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>					N/A	N/A	5,955 €	15,884 €	Aggregate HCPs	Aggregate HCPs	Optional	
	<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>					N/A	N/A	number	number	number	number	Optional	
	<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>					N/A	N/A	%	%	%	%	N/A	
HCOs	<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCO</b> (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)												
		Cyprus Society of Cardiology				Yearly amount	2,800 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Ιατρικός Σύλλογος Λεμεσού				Yearly amount	950 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Εταιρεία Διαβητολογίας Κύπρου				Yearly amount	5,400 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Εταιρεία Υπέρτασης Κύπρου				Yearly amount	1,000 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Ενδοκρινολογική Εταιρεία Κύπρου				Yearly amount	1,800 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Cyprus Diabetes and Metabolic Institute for Research & Education for Diabetes				Yearly amount	1,000 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Παθολογική Εταιρεία Κύπρου				Yearly amount	1,500 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
		Ιατρικός Σύλλογος Ιπποκράτης				Yearly amount	600 €	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Yearly amount	Optional
	<b>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</b>												
	<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>					Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Aggregate HCOs	Optional	
	<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>					number	number	number	number	number	number	Optional	
	<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>					%	%	%	%	%	%	N/A	
R & D	<b>AGGREGATE DISCLOSURE</b>												
		Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1										TOTAL AMOUNT	OPTIONAL